2月12日,石药集团宣布,集团全资附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司共同开发HER2双抗ADC药物普康安尼妥单抗(JSKN003)在中国开展的用于HER2 阳性晚期结直肠癌III期临床试验完成首例患者给药。关于结直肠癌结直肠癌是全球最常见的恶性肿瘤之一。中国是结直肠癌高发国家,每年新发病例数超过 50万,约 83%的患者首诊即中晚期,且44%存在肝、肺等远处转移。尽管...
Source Link2月12日,石药集团宣布,集团全资附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司共同开发HER2双抗ADC药物普康安尼妥单抗(JSKN003)在中国开展的用于HER2 阳性晚期结直肠癌III期临床试验完成首例患者给药。关于结直肠癌结直肠癌是全球最常见的恶性肿瘤之一。中国是结直肠癌高发国家,每年新发病例数超过 50万,约 83%的患者首诊即中晚期,且44%存在肝、肺等远处转移。尽管...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.